CervoMed (CRVO) announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Before joining CervoMed, Dr. Winton served as COO at Inozyme Pharma (INZY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed announces development program, benefits of neflamapimod
- H.C. Wainwright sets CervoMed price target into FDA clarity
- CervoMed price target raised to $31 from $15 at D. Boral Capital
- CervoMed’s Promising Developments and Financial Stability Drive Buy Rating with $20 Price Target
- CervoMed price target lowered to $16 from $20 at Roth Capital